

1376 Miners Dr., Ste. 101, Lafayette, CO 80026 P: 303-531-0861 E: support@quicksilverscientific.com

### PRODUCT SPECIFICATION AND CERTIFICATE OF ANALYSIS

Document #	FP.076	Rev.	Effective Date			
Product Code#	QSCBSSP01	3	04/29/2020			
CBD SYNERGIES	CBD SYNERGIES – SP (SLEEP FORMULA)					

Lot Number:	CBSSP2102/1
Manufacturing Date:	6/2021
Bottle Size:	50 mL
Storage Recommendation:	Room Temperature
Shelf Life / EXP Date:	The freshness is commonly mainteained two years after manufacturing date.

7/7/21

### **Final Product Tests**

Test Performed	Method	Specification	Result	Pass/Fail
Aerobic Plate Count	USP2021	≤ 10 <sup>5</sup> cfu/mL	Conforms	☐ Pass☐ Fail
Coliforms	AOAC 991.14	≤ 100cfu/mL	Conforms	☐ Pass☐ Fail
E. Coli	USP2022	Absent	Conforms	☐ Pass☐ Fail
Staph aureus	USP2022	Absent	Conforms	☐ Pass☐ Fail
Yeast/Mold	USP2021	≤ 1000cfu/mL	Conforms	☐ Pass☐ Fail
Salmonella	USP2022	Absent	Conforms	☐ Pass☐ Fail
Pseudo. aeruginosa	mUSP62	Absent	Conforms	☐ Pass☐ Fail
Arsenic	ICPMS	≤ 2ppm	<0.005	☐ Pass ☐ Fail
Cadmium	ICPMS	≤ 2ppm	<0.005	☐ Pass ☐ Fail
Lead	ICPMS	≤ 1ppm	<0.005	☐ Pass ☐ Fail
Mercury	ICPMS	≤ 1ppm	<0.005	☐ Pass ☐ Fail
Liposome size	DLS	10nm – 70nm	Conforms	☐ Pass ☐ Fail
5-HTP	HPLC	≥16 mg/2mL	19.294/2ml	☐ Pass ☐ Fail
Melatonin	HPLC	≥0.25 mg/2mL	.300mg/2ml	☐ Pass ☐ Fail
Cannabidiol	LC/MS/MS or HPLC	≥8 mg/2mL	12.46/2ml	☐ Pass ☐ Fail



1376 Miners Dr., Ste. 101, Lafayette, CO 80026 P: 303-531-0861 E: support@quicksilverscientific.com

## PRODUCT SPECIFICATION AND CERTIFICATE OF ANALYSIS

Document # FP.076	FP.076	Rev.	Effective Date
Product Code#	QSCBSSP01	3	04/29/2020
	S - SP (SLEEP FORMULA)		

Test Performed	Method	Specification	Result	Pass/Fail
THC	LC/MS/MS or HPLC	≤ 0.3%	0.019%	☐ Pass☐ Fail
CBDA	LC/MS/MS or HPLC	For Information Only	Conforms	N/A
CBG	LC/MS/MS or HPLC	For Information Only	Conforms	N/A
CBN	LC/MS/MS or HPLC	For Information Only	Conforms	N/A
CBC	LC/MS/MS or HPLC	For Information Only	Conforms	N/A
CBDA	LC/MS/MS or HPLC	For Information Only	Conforms	N/A

<sup>\*100%</sup> label claim at the time of manufacture

Manufacturer	Lot Number
CBD Universe	210392

**NOTES:** 

<sup>\*\*</sup>Solvent and Pesticide testing performed annually



Order No. 525053

Sample No. 1087892

July 02, 2021

**QUICKSILVER SCIENTIFIC** 

Attn: Erin Bingham 1376 Miners Drive Suite 101 Lafayette, CO 80026

SAMPLE INFORMATION

DescriptionCBD SynergiesLot NumberCBSSP2102/1

Category (Type) Non-Inhalable Orally Consumed Concentrate (Tincture)

Received June 30, 2021

**ANALYTICAL RESULTS** 

Analysis Cannabinoid Profile

Instrument Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS)

Method MF12D012

**Analysis Date** June 30, 2021 to July 02, 2021

Cannabinoid	mg/g	%	mg/ml
Δ8-THC	ND	ND	ND
Δ9-ΤΗС	0.1971	0.01971	0.2107
Δ9-ΤΗCΑ	ND	ND	ND
THCV	0.0044	0.00044	0.0047
THCVA	ND	ND	ND
CBD	5.3167	0.53167	5.6835
CBDA	ND	ND	ND
CBC	0.2418	0.02418	0.2585
CBCA	ND	ND	ND
CBDV	0.0458	0.00458	0.0489
CBG	0.0967	0.00967	0.1034
CBGA	ND	ND	ND
CBN	0.0101	0.00101	0.0108
Total THC	0.1971	0.01971	0.2107
Total CBD	5.3167	0.53167	5.6835
Total Cannabinoids	5.9125	0.59125	6.3204
Total Active Cannabinoids	5.9125	0.59125	6.3204
g/ml Conversion Factor	1.069		

Reported by **Anresco, Inc.** 

Derek Moy Senior Analyst

July 02, 2021

Limit of Detection: 0.0008 mg/g Limit of Quantitation: 0.0025 mg/g

ND = None Detected

<LOQ = Below Limit of Quantitation <LOD = Below Limit of Detection

If there are any questions with this report, please contact "compliance@anresco.com".



1376 Miners Dr., Ste. 101, Lafayette, CO 80026 P: 303-531-0861 E: support@quicksilverscientific.com

### PRODUCT SPECIFICATION AND CERTIFICATE OF ANALYSIS

Document #	FP.076	Rev.	Effective Date			
Product Code#	QSCBSSP01	3	04/29/2020			
CBD SYNERGIES	CBD SYNERGIES – SP (SLEEP FORMULA)					

Lot Number:	CBSSP2102/1
Manufacturing Date:	6/2021
Bottle Size:	50 mL
Storage Recommendation:	Room Temperature
Shelf Life / EXP Date:	The freshness is commonly mainteained two years after manufacturing date.

7/7/21

### **Final Product Tests**

Test Performed	Method	Specification	Result	Pass/Fail
Aerobic Plate Count	USP2021	≤ 10 <sup>5</sup> cfu/mL	Conforms	☐ Pass☐ Fail
Coliforms	AOAC 991.14	≤ 100cfu/mL	Conforms	☐ Pass☐ Fail
E. Coli	USP2022	Absent	Conforms	☐ Pass☐ Fail
Staph aureus	USP2022	Absent	Conforms	☐ Pass☐ Fail
Yeast/Mold	USP2021	≤ 1000cfu/mL	Conforms	☐ Pass☐ Fail
Salmonella	USP2022	Absent	Conforms	☐ Pass☐ Fail
Pseudo. aeruginosa	mUSP62	Absent	Conforms	☐ Pass☐ Fail
Arsenic	ICPMS	≤ 2ppm	<0.005	☐ Pass ☐ Fail
Cadmium	ICPMS	≤ 2ppm	<0.005	☐ Pass ☐ Fail
Lead	ICPMS	≤ 1ppm	<0.005	☐ Pass ☐ Fail
Mercury	ICPMS	≤ 1ppm	<0.005	☐ Pass ☐ Fail
Liposome size	DLS	10nm – 70nm	Conforms	☐ Pass ☐ Fail
5-HTP	HPLC	≥16 mg/2mL	19.294/2ml	☐ Pass ☐ Fail
Melatonin	HPLC	≥0.25 mg/2mL	.300mg/2ml	☐ Pass ☐ Fail
Cannabidiol	LC/MS/MS or HPLC	≥8 mg/2mL	12.46/2ml	☐ Pass ☐ Fail



1376 Miners Dr., Ste. 101, Lafayette, CO 80026 P: 303-531-0861 E: support@quicksilverscientific.com

## PRODUCT SPECIFICATION AND CERTIFICATE OF ANALYSIS

Document # FP.076	FP.076	Rev.	Effective Date
Product Code#	QSCBSSP01	3	04/29/2020
	S - SP (SLEEP FORMULA)		

Test Performed	Method	Specification	Result	Pass/Fail
THC	LC/MS/MS or HPLC	≤ 0.3%	0.019%	☐ Pass☐ Fail
CBDA	LC/MS/MS or HPLC	For Information Only	Conforms	N/A
CBG	LC/MS/MS or HPLC	For Information Only	Conforms	N/A
CBN	LC/MS/MS or HPLC	For Information Only	Conforms	N/A
CBC	LC/MS/MS or HPLC	For Information Only	Conforms	N/A
CBDA	LC/MS/MS or HPLC	For Information Only	Conforms	N/A

<sup>\*100%</sup> label claim at the time of manufacture

hemp tincture. 8mg canna  Manufacturer	Lot Number
CBD Universe	210392

**NOTES:** 

<sup>\*\*</sup>Solvent and Pesticide testing performed annually



1960 Cherry Street Louisville, CO 80027 (303) 531-0861

gs.labtesting@quicksilverscientific.com
Lab Accredidation Number: 6052.01

Contact Name: Contact Information: Madalyn Morley

qs.testresults@quicksilverscientific.com

Sample Information

Product: CBD Synergies SP
Description: Lipsome
Lot/Batch#: CBSSP2102/1

Date Received: Date Analyzed:

Report Date:

June 30, 2021 July 2, 2021

July 2, 2021

#### **Certificate of Analysis**

Analyte	Method	Reporting Limit	Result	Units
As	QS-LIPO-HM-ICP/USP 730	0.005	< 0.005	ppm
Cd	QS-LIPO-HM-ICP/USP 730	0.005	< 0.005	ppm
Hg	QS-LIPO-HM-ICP/USP 730	0.005	< 0.005	ppm
Pb	QS-LIPO-HM-ICP/USP 730	0.005	< 0.005	ppm

Report Approved by:

Renee A Cortez Quality Assurance Officer

 $<sup>{}^{*}</sup>$  Samples were analyzed for analytes that are not accredited by A2LA .

<sup>\*\*</sup>The results generated on this report correlate only to the samples received and tested by the laboratory. The laboratory is not responsible for sampling, therefore results are based solely on samples submitted to the laboratory.



July 06, 2021

### **QUICKSILVER SCIENTIFIC**

Attn: Erin Bingham 1376 Miners Drive Suite 101 Lafayette, CO 80026 Order No. 525053 Sample No. 1087892

#### **SAMPLE INFORMATION**

DescriptionCBD SynergiesLot NumberCBSSP2102/1ReceivedJune 30, 2021

### **ANALYTICAL RESULTS**

**Analysis Date** June 30, 2021 to July 06, 2021

Findings	Analysis	Results	Method
	Standard Plate Count	<10 cfu/g	FDA BAM
	Yeast	<10 cfu/g	AOAC 2014.05
	Mold	<10 cfu/g	AOAC 2014.05
	Coliforms	<10 cfu/g	FDA BAM - ECC AGAR
	Escherichia coli	<10 cfu/g	FDA BAM - ECC AGAR
	Pseudomonas	<10 cfu/g	CMMEF
	Salmonella	Negative /1g	AOAC 2016.01
	Staphylococcus aureus	<10 cfu/g	AOAC 2003.07

Reported by **Anresco, Inc.** 



If there are any questions with this report, please contact "compliance@anresco.com".



July 02, 2021

**QUICKSILVER SCIENTIFIC** 

Attn: Erin Bingham 1376 Miners Drive Suite 101 Lafayette, CO 80026 Order No. 525053 Sample No. 1087892

#### SAMPLE INFORMATION

DescriptionCBD SynergiesLot NumberCBSSP2102/1

Category (Type) Non-Inhalable Orally Consumed Concentrate (Tincture)

Received June 30, 2021

**ANALYTICAL RESULTS** 

Analysis Pesticide Screen Pass

**Instrument** Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem

Mass Spectrometry (GC-MS/MS)

Method MF 21P030

Analysis Date June 30, 2021 to July 02, 2021

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.02/0.06	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0.20/0.06	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.02/0.06	ND	0.02	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.08	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0.30	ND	1.0	Pass
Cypermethrin	0.10/0.30	ND	1.0	Pass
Daminozide	0.02/0.06	ND	0.02	Pass
DDVP (Dichlorvos)	0.02/0.06	ND	0.02	Pass
Diazinon	0.02/0.06	ND	0.2	Pass
Dimethoate	0.02/0.06	ND	0.02	Pass
Dimethomorph	0.02/0.06	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.02/0.06	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass
Fipronil	0.02/0.06	ND	0.02	Pass

If there are any questions with this report, please contact "compliance@anresco.com".

**Anresco Laboratories** www.anresco.com 1375 Van Dyke Ave,. San Francisco, CA 94124 page **1** of **2** Report ID: 2

Sample #: 1087892 Batch #: CBSSP2102/1



Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxanil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.02/0.06	ND	5.0	Pass
Metalaxyl	0.02/0.06	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.02/0.06	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.02/0.06	ND	0.5	Pass
Oxamyl	0.02/0.06	ND	0.2	Pass
Paclobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.04/0.10	ND	0.2	Pass
Permethrins	0.10/0.30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.02/0.06	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.02/0.06	ND	0.02	Pass
Pyrethrins	0.10/0.30	ND	1.0	Pass
Pyridaben	0.02/0.06	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.02/0.06	ND	0.02	Pass
Tebuconazole	0.02/0.06	ND	2.0	Pass
Thiaclorprid	0.02/0.06	ND	0.02	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	0.02/0.06	ND	30.0	Pass

Reported by ND = None Detected Anresco, Inc.



July 02, 2021

If there are any questions with this report, please contact "compliance@anresco.com".



ISO/IEC 17025:2017 Accreditation #: 75696 lab@summitnutritional.com

Report Number: 210630 012-03

Date Reported: 7/7/2021 2:18:05 PM

**Sample Details** 

Product #: CBD Synergies SP (Sleep Formula)
Description: CBD Synergies SP (Sleep Formula)

Lot #: CBSSP2102/1

Received: 6/30/2021 12:53:34 PM

Sample Details:

**Customer Information** 

Quicksilver Scientific 1376 Miners Drive 101 Lafayette, CO 80026

Certificate of Analysis

		, , , , , , , , , , , , , , , , , , ,			
Chemistry	Method	Specifications	Result	Units	
Amino Acids					
5-Hydroxy-L-Tryptophan	WI.HPLC.329.06	> 16	19.294	mg/serving	
Botanicals and Nutraceuticals					
Melatonin	SNL.HPLC.330	> 0.25	0.300	mg/serving	
Physical					
Specific Gravity	SNL.USP.841.01		1.105	g/mL	
Serving Size	SNL.MA.210		2.00	mL	

Report Approved by:

Joel Nelson Laboratory Manager \*= Please review Client Specifications

Report Numbers that have been revised or amended will include a

revision number.

This Certificate of Analysis shall not be reproduced, except in full, without written permission from the laboratory. This Certificate of Analysis results apply to the items tested. Further information is available, upon request, when needed for the interpretation of the test results.

This Certificate of Analysis is provided for the exclusive use of the addressee. The laboratory accepts no responsibility/liability except for the due performance of inspection and/or analysis in good faith.